Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics.
This report contains market size and forecasts of Long-Acting Schizophrenia Drug in Global, including the following market information:
Global Long-Acting Schizophrenia Drug Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Long-Acting Schizophrenia Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Oral Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Long-Acting Schizophrenia Drug include Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Sumitomo Dainippon Pharma, Allergan, Novartis and Cardinal Health, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Long-Acting Schizophrenia Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Long-Acting Schizophrenia Drug Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, by Type, 2022 (%)
Oral
Injection
Global Long-Acting Schizophrenia Drug Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Pharmacies
Other
Global Long-Acting Schizophrenia Drug Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Long-Acting Schizophrenia Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Long-Acting Schizophrenia Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Teva
Eli Lilly
Bristol Myers Squibb
AstraZeneca
Sumitomo Dainippon Pharma
Allergan
Novartis
Cardinal Health
Sun Pharmaceutical Industries
GlaxoSmithKline
Sanis Health
Qilu Pharmaceutical
Otsuka Pharmaceutical
Vanda Pharmaceuticals
H.Lundbeck
Organon
Hansoh
Hengrui
Nhwa Group
Yangtze River Pharmaceutical Group
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Long-Acting Schizophrenia Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Long-Acting Schizophrenia Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Long-Acting Schizophrenia Drug Overall Market Size
2.1 Global Long-Acting Schizophrenia Drug Market Size: 2022 VS 2030
2.2 Global Long-Acting Schizophrenia Drug Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Long-Acting Schizophrenia Drug Players in Global Market
3.2 Top Global Long-Acting Schizophrenia Drug Companies Ranked by Revenue
3.3 Global Long-Acting Schizophrenia Drug Revenue by Companies
3.4 Top 3 and Top 5 Long-Acting Schizophrenia Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Long-Acting Schizophrenia Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Long-Acting Schizophrenia Drug Players in Global Market
3.6.1 List of Global Tier 1 Long-Acting Schizophrenia Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Long-Acting Schizophrenia Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Long-Acting Schizophrenia Drug Market Size Markets, 2022 & 2030
4.1.2 Oral
4.1.3 Injection
4.2 By Type - Global Long-Acting Schizophrenia Drug Revenue & Forecasts
4.2.1 By Type - Global Long-Acting Schizophrenia Drug Revenue, 2018-2023
4.2.2 By Type - Global Long-Acting Schizophrenia Drug Revenue, 2023-2030
4.2.3 By Type - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Long-Acting Schizophrenia Drug Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Pharmacies
5.1.4 Other
5.2 By Application - Global Long-Acting Schizophrenia Drug Revenue & Forecasts
5.2.1 By Application - Global Long-Acting Schizophrenia Drug Revenue, 2018-2023
5.2.2 By Application - Global Long-Acting Schizophrenia Drug Revenue, 2023-2030
5.2.3 By Application - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Long-Acting Schizophrenia Drug Market Size, 2022 & 2030
6.2 By Region - Global Long-Acting Schizophrenia Drug Revenue & Forecasts
6.2.1 By Region - Global Long-Acting Schizophrenia Drug Revenue, 2018-2023
6.2.2 By Region - Global Long-Acting Schizophrenia Drug Revenue, 2023-2030
6.2.3 By Region - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Long-Acting Schizophrenia Drug Revenue, 2018-2030
6.3.2 US Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.3.3 Canada Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.3.4 Mexico Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Long-Acting Schizophrenia Drug Revenue, 2018-2030
6.4.2 Germany Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4.3 France Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4.4 U.K. Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4.5 Italy Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4.6 Russia Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4.7 Nordic Countries Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.4.8 Benelux Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Long-Acting Schizophrenia Drug Revenue, 2018-2030
6.5.2 China Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.5.3 Japan Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.5.4 South Korea Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.5.5 Southeast Asia Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.5.6 India Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Long-Acting Schizophrenia Drug Revenue, 2018-2030
6.6.2 Brazil Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.6.3 Argentina Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue, 2018-2030
6.7.2 Turkey Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.7.3 Israel Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.7.4 Saudi Arabia Long-Acting Schizophrenia Drug Market Size, 2018-2030
6.7.5 UAE Long-Acting Schizophrenia Drug Market Size, 2018-2030
7 Players Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Corporate Summary
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Major Product Offerings
7.1.4 Johnson & Johnson Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.1.5 Johnson & Johnson Key News
7.2 Teva
7.2.1 Teva Corporate Summary
7.2.2 Teva Business Overview
7.2.3 Teva Long-Acting Schizophrenia Drug Major Product Offerings
7.2.4 Teva Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.2.5 Teva Key News
7.3 Eli Lilly
7.3.1 Eli Lilly Corporate Summary
7.3.2 Eli Lilly Business Overview
7.3.3 Eli Lilly Long-Acting Schizophrenia Drug Major Product Offerings
7.3.4 Eli Lilly Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.3.5 Eli Lilly Key News
7.4 Bristol Myers Squibb
7.4.1 Bristol Myers Squibb Corporate Summary
7.4.2 Bristol Myers Squibb Business Overview
7.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Major Product Offerings
7.4.4 Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.4.5 Bristol Myers Squibb Key News
7.5 AstraZeneca
7.5.1 AstraZeneca Corporate Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Long-Acting Schizophrenia Drug Major Product Offerings
7.5.4 AstraZeneca Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.5.5 AstraZeneca Key News
7.6 Sumitomo Dainippon Pharma
7.6.1 Sumitomo Dainippon Pharma Corporate Summary
7.6.2 Sumitomo Dainippon Pharma Business Overview
7.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Major Product Offerings
7.6.4 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.6.5 Sumitomo Dainippon Pharma Key News
7.7 Allergan
7.7.1 Allergan Corporate Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Long-Acting Schizophrenia Drug Major Product Offerings
7.7.4 Allergan Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.7.5 Allergan Key News
7.8 Novartis
7.8.1 Novartis Corporate Summary
7.8.2 Novartis Business Overview
7.8.3 Novartis Long-Acting Schizophrenia Drug Major Product Offerings
7.8.4 Novartis Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.8.5 Novartis Key News
7.9 Cardinal Health
7.9.1 Cardinal Health Corporate Summary
7.9.2 Cardinal Health Business Overview
7.9.3 Cardinal Health Long-Acting Schizophrenia Drug Major Product Offerings
7.9.4 Cardinal Health Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.9.5 Cardinal Health Key News
7.10 Sun Pharmaceutical Industries
7.10.1 Sun Pharmaceutical Industries Corporate Summary
7.10.2 Sun Pharmaceutical Industries Business Overview
7.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Major Product Offerings
7.10.4 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.10.5 Sun Pharmaceutical Industries Key News
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Corporate Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Major Product Offerings
7.11.4 GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.11.5 GlaxoSmithKline Key News
7.12 Sanis Health
7.12.1 Sanis Health Corporate Summary
7.12.2 Sanis Health Business Overview
7.12.3 Sanis Health Long-Acting Schizophrenia Drug Major Product Offerings
7.12.4 Sanis Health Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.12.5 Sanis Health Key News
7.13 Qilu Pharmaceutical
7.13.1 Qilu Pharmaceutical Corporate Summary
7.13.2 Qilu Pharmaceutical Business Overview
7.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Major Product Offerings
7.13.4 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.13.5 Qilu Pharmaceutical Key News
7.14 Otsuka Pharmaceutical
7.14.1 Otsuka Pharmaceutical Corporate Summary
7.14.2 Otsuka Pharmaceutical Business Overview
7.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Major Product Offerings
7.14.4 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.14.5 Otsuka Pharmaceutical Key News
7.15 Vanda Pharmaceuticals
7.15.1 Vanda Pharmaceuticals Corporate Summary
7.15.2 Vanda Pharmaceuticals Business Overview
7.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Major Product Offerings
7.15.4 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.15.5 Vanda Pharmaceuticals Key News
7.16 H.Lundbeck
7.16.1 H.Lundbeck Corporate Summary
7.16.2 H.Lundbeck Business Overview
7.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Major Product Offerings
7.16.4 H.Lundbeck Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.16.5 H.Lundbeck Key News
7.17 Organon
7.17.1 Organon Corporate Summary
7.17.2 Organon Business Overview
7.17.3 Organon Long-Acting Schizophrenia Drug Major Product Offerings
7.17.4 Organon Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.17.5 Organon Key News
7.18 Hansoh
7.18.1 Hansoh Corporate Summary
7.18.2 Hansoh Business Overview
7.18.3 Hansoh Long-Acting Schizophrenia Drug Major Product Offerings
7.18.4 Hansoh Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.18.5 Hansoh Key News
7.19 Hengrui
7.19.1 Hengrui Corporate Summary
7.19.2 Hengrui Business Overview
7.19.3 Hengrui Long-Acting Schizophrenia Drug Major Product Offerings
7.19.4 Hengrui Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.19.5 Hengrui Key News
7.20 Nhwa Group
7.20.1 Nhwa Group Corporate Summary
7.20.2 Nhwa Group Business Overview
7.20.3 Nhwa Group Long-Acting Schizophrenia Drug Major Product Offerings
7.20.4 Nhwa Group Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.20.5 Nhwa Group Key News
7.21 Yangtze River Pharmaceutical Group
7.21.1 Yangtze River Pharmaceutical Group Corporate Summary
7.21.2 Yangtze River Pharmaceutical Group Business Overview
7.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Major Product Offerings
7.21.4 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.21.5 Yangtze River Pharmaceutical Group Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Long-Acting Schizophrenia Drug Market Opportunities & Trends in Global Market
Table 2. Long-Acting Schizophrenia Drug Market Drivers in Global Market
Table 3. Long-Acting Schizophrenia Drug Market Restraints in Global Market
Table 4. Key Players of Long-Acting Schizophrenia Drug in Global Market
Table 5. Top Long-Acting Schizophrenia Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Long-Acting Schizophrenia Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Long-Acting Schizophrenia Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Long-Acting Schizophrenia Drug Product Type
Table 9. List of Global Tier 1 Long-Acting Schizophrenia Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Long-Acting Schizophrenia Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Long-Acting Schizophrenia Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Long-Acting Schizophrenia Drug Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2023-2030
Table 30. Johnson & Johnson Corporate Summary
Table 31. Johnson & Johnson Long-Acting Schizophrenia Drug Product Offerings
Table 32. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 33. Teva Corporate Summary
Table 34. Teva Long-Acting Schizophrenia Drug Product Offerings
Table 35. Teva Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 36. Eli Lilly Corporate Summary
Table 37. Eli Lilly Long-Acting Schizophrenia Drug Product Offerings
Table 38. Eli Lilly Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 39. Bristol Myers Squibb Corporate Summary
Table 40. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product Offerings
Table 41. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 42. AstraZeneca Corporate Summary
Table 43. AstraZeneca Long-Acting Schizophrenia Drug Product Offerings
Table 44. AstraZeneca Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 45. Sumitomo Dainippon Pharma Corporate Summary
Table 46. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product Offerings
Table 47. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 48. Allergan Corporate Summary
Table 49. Allergan Long-Acting Schizophrenia Drug Product Offerings
Table 50. Allergan Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 51. Novartis Corporate Summary
Table 52. Novartis Long-Acting Schizophrenia Drug Product Offerings
Table 53. Novartis Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 54. Cardinal Health Corporate Summary
Table 55. Cardinal Health Long-Acting Schizophrenia Drug Product Offerings
Table 56. Cardinal Health Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 57. Sun Pharmaceutical Industries Corporate Summary
Table 58. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product Offerings
Table 59. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 60. GlaxoSmithKline Corporate Summary
Table 61. GlaxoSmithKline Long-Acting Schizophrenia Drug Product Offerings
Table 62. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 63. Sanis Health Corporate Summary
Table 64. Sanis Health Long-Acting Schizophrenia Drug Product Offerings
Table 65. Sanis Health Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 66. Qilu Pharmaceutical Corporate Summary
Table 67. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product Offerings
Table 68. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 69. Otsuka Pharmaceutical Corporate Summary
Table 70. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product Offerings
Table 71. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 72. Vanda Pharmaceuticals Corporate Summary
Table 73. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product Offerings
Table 74. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 75. H.Lundbeck Corporate Summary
Table 76. H.Lundbeck Long-Acting Schizophrenia Drug Product Offerings
Table 77. H.Lundbeck Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 78. Organon Corporate Summary
Table 79. Organon Long-Acting Schizophrenia Drug Product Offerings
Table 80. Organon Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 81. Hansoh Corporate Summary
Table 82. Hansoh Long-Acting Schizophrenia Drug Product Offerings
Table 83. Hansoh Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 84. Hengrui Corporate Summary
Table 85. Hengrui Long-Acting Schizophrenia Drug Product Offerings
Table 86. Hengrui Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 87. Nhwa Group Corporate Summary
Table 88. Nhwa Group Long-Acting Schizophrenia Drug Product Offerings
Table 89. Nhwa Group Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
Table 90. Yangtze River Pharmaceutical Group Corporate Summary
Table 91. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product Offerings
Table 92. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Long-Acting Schizophrenia Drug Segment by Type in 2022
Figure 2. Long-Acting Schizophrenia Drug Segment by Application in 2022
Figure 3. Global Long-Acting Schizophrenia Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Long-Acting Schizophrenia Drug Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Long-Acting Schizophrenia Drug Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Long-Acting Schizophrenia Drug Revenue in 2022
Figure 8. By Type - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 9. By Application - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 10. By Region - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 11. By Country - North America Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 12. US Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 16. Germany Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 17. France Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 24. China Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 28. India Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 30. Brazil Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2030
Figure 33. Turkey Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2030
Figure 37. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Teva Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Eli Lilly Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. AstraZeneca Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Allergan Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novartis Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Cardinal Health Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sanis Health Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. H.Lundbeck Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Organon Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Hansoh Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Hengrui Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Nhwa Group Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
